US FDA Approve Areva’s Verapamil HCl Injection for the US Market
Areva Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Verapamil HCl, USP in 5mg/2ml and 10mg/4ml vial. It is an AP-rated generic injection to ISOPTIN® INJECTION
“Areva Pharmaceuticals is very pleased to announce the approval of Verapamil HCl. This approval further cements Areva’s commitment to bringing sterile injectable products to produced exclusively for US and European markets,” says Irene Swaminathan, President & Chairwomen of Areva Pharmaceuticals.
Verapamil injection USP
Verapamil HCL is a calcium-channel blocker; used for angina, HTN, and supraventricular tachyarrhythmias; class IV antiarrhythmic agent; more effective than digoxin for controlling ventricular rate in AFIB.
About Areva Pharmaceutical
Areva Pharmaceuticals Inc., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, and more streamlined in practice for US Healthcare providers. Areva ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. Our Mission is to bring “ VALUE BEYONG EACH VIAL”